用户名:  密码:   
网站首页即时通讯活动公告最新消息科技前沿学人动向两岸三地人在海外历届活动关于我们联系我们申请加入
栏目导航 — 美国华裔教授专家网活动公告学术论坛
关键字  范围   
 
SABPA Science and Technology Forum XII - Promising Future of Clinical Development(3/29 San Diego)
2014/3/5 14:29:17 | 浏览:1850 | 评论:0

SABPA Science and Technology Forum XII - Promising Future of Clinical Development(3/29 San Diego)

The Promising Future of Clinical Development in San Diego

SABPA Science and Technology Forum XII

Co-organized with UCSD Moores Cancer Center

Date:March 29, 2014(Saturday), 8:30am to 1:00pm(Breakfast and lunch will be provided.)
Location:Institute of Americas, UCSD, 10111 North Torrey Pines Road, La Jolla, CA 92037
Registrationhttps://www.123signup.com/register?id=ddpvm
$20 for online registration(by March 27, 2014), $10 for students and post-docs, $40 for on-site registration

San Diego is a vibrant and successful biotech hub consisting of over 400 biotech/pharma companies and a cluster of world-renowned academic research institutions. From Rituximab, a biologic drug approved over a decade ago, to the most recent Crizotinib, a small molecule drug, biotech/pharma companies in San Diego are continuing to produce innovative medicines to treat patients with cancer, diabetes, inflammation and other diseases. While strong in its biotech/pharma R&D functions, San Diego is emerging as a center for clinical trials, an essential part of the drug development process. Furthermore, as clinical trials have become increasingly more global oriented, San Diego is poised to take a leadership role in conducting international clinical collaborations, particularly with Asian Pacific countries.

At the SABPA Science & Technology Forum XII, we bring together leaders in academic and pharma/biotech industry to discuss how to move drugs quickly and efficiently to patients. Speakers from Moores cancer center and pharma companies will present their visions and efforts to strengthen the clinical trial capability in San Diego to better serve the need of local biotech/pharma community and to make San Diego a designated center for personalized cancer therapy. Speakers from leading clinical centers in China will provide their insights in how biotech/pharma companies in San Diego can leverage the emerging and rapidly growing clinical market in China to accelerate the clinical development processes.

Confirmed Speakers:

  • Scott M. Lippman, M.D.
    Professor of Medicine, Director, UCSD Moores Cancer Center
  • Razelle Kurzrock, M.D.
    Professor of Medicine, Director, Division of Clinical Science, UCSD Moores Cancer Center
  • Andreas Koester, M.D., Ph.D.
    VP of Clinical Trial Innovation & External Alliances. Janssen, Pharmaceutical Companies of Johnson & Johnson
  • Steffan Ho, M.D., Ph.D.
    Senior Director, Early Development and Translational Oncology, Pfizer
  • Eric Groves, M.D., Ph.D.
    VP, Global Strategic Drug Development Innovation at Quintiles
  • Dan Zhang, Ph.D.
    CEO, Fountain Medical Development Ltd.
  • Ida Deichaite, Ph.D.
    Director of Industry Relations, UCSD Moores Cancer Center
相关栏目:『学术论坛
海南大学第六届国际青年学者论坛公告 2024-11-16 [45]
重磅!2024世界中文大会即将在京举行! 2024-11-16 [40]
第三届新医科人才评价与发展论坛通知 2024-09-14 [1393]
Represent Your Program at the 2024 AMS Online Fall Graduate School Fair 2024-08-15 [2493]
Young Mathematicians Conference:August 13-15,2024 2024-07-09 [4456]
研究了 3 万条审稿意见,竟发了篇 Nature 子刊,审稿人:这是我见过最「可怕」的作者 2024-06-13 [5520]
2024年CCF量子计算大会开放注册 2024-06-04 [4962]
UCLA:Industrial Polyphony:Voices and Sounds in the Poetry of Contemporary China's Worker 2024-05-08 [2548]
UCLA:China without Coasts 2024-04-26 [2281]
UCLA:The Gender Politics of Superstition in the Chinese Revolution 2024-04-26 [1510]
相关栏目更多文章
最新图文:
:日本政府《氢能利用进度表》 :美国《2016-2045年新兴科技趋势报告》 :天津工业大学“经纬英才”引进计划 :浙江财经大学国际青年学者论坛的邀请函 (10/31-11/1) :美国加大审查范围 北大多名美国留学生遭联邦调查局质询 :天安门广场喜迎“十一”花团锦簇的美丽景象 马亮:做院长就能够发更多论文?论文发表是不是一场“权力的游戏”? :印裔人才在美碾压华裔:我们可以从印度教育中学到什么?
更多最新图文
更多《即时通讯》>>
 
打印本文章
 
您的名字:
电子邮件:
留言内容:
注意: 留言内容不要超过4000字,否则会被截断。
未 审 核:  是
  
关于我们联系我们申请加入后台管理设为主页加入收藏
美国华裔教授专家网版权所有,谢绝拷贝。如欲选登或发表,请与美国华裔教授专家网联系。
Copyright © 2024 ScholarsUpdate.com. All Rights Reserved.